At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018

  • Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020
  • Focused and taking steps to become stronger and more integrated through centralized manufacturing, development and business services
  • Poised for next growth phase, anticipated to begin in 2018

Boston, May 31, 2017 – Today Novartis holds its fourth annual Meet Novartis Management event at its research headquarters in Cambridge, MA, giving …

/by

At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018

  • Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020
  • Focused and taking steps to become stronger and more integrated through centralized manufacturing, development and business services
  • Poised for next growth phase, anticipated to begin in 2018

Boston, May 31, 2017 – Today Novartis holds its fourth annual Meet Novartis Management event at its research headquarters in Cambridge, MA, giving …

/by

Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency

  • Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira®* and Remicade®†
  • Comprehensive data packages demonstrate each biosimilar matches its respective reference medicine in terms of quality, efficacy and safety
  • These regulatory submissions follow soon after two positive CHMP opinions** for Sandoz biosimilars etanercept and rituximab further reinforcing Sandoz immunology pipeline and the broader Novartis immunology portfolio

    • …

/by

Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued

  • Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact
    • Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications
    • Entresto (USD 84 million) steadily growing with better access in US and EU
    • Gilenya (USD 722 million, +5% cc) grew mainly driven by volume
    • Excluding Gleevec/Glivec, Oncology grew +7% (cc) driven mainly by Promacta/Revolade, Jakavi, Tafinlar + Mekinist and Tasigna
  • Core[1] operating income down 5% (cc) due to generic erosion and increased investments, mainly …
/by

Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*

  • Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases.  Biosimilar rituximab also recommended to treat blood cancers
  • Comprehensive data packages, confirming Sandoz biosimilars rituximab and etanercept match their respective reference medicines, were the basis for CHMP decisions
  • Subject to EC** approval, Sandoz market leadership position extended as the only company to have five approved biosimilars in Europe1

Holzkirchen, April 21, 2017 – Sandoz …

/by

Major Novartis investment in Slovenia reinforces commitment to largest Sandoz product and business

  • Total investment of EUR 105 million in Prevalje site reinforces commitment to largest Sandoz business, Anti-Infectives, and single largest global product, broad-spectrum antibiotic amoxicillin-clavulanic acid.
  • The investment will bring 150 new jobs, more than doubling the number of employees at Prevalje over six years.
  • The project, scheduled for completion in 2019, will be the largest Novartis investment in Slovenia to date.

Prevalje, April 11, 2017 – A foundation stone for the new production plant for a broad- …

/by

Sandoz digital “Scientific Standalone” event will help drive access to medical information in field of cardiovascular therapies

  • Sandoz Scientific Standalone event — “Reach Targets, Save Lives” – aims at increasing access to information in the field of cardiovascular therapies in Central & Eastern Europe and Middle East & Africa (CEEMEA)
  • Lectures by leading cardiologists and internal medicine specialists will be recorded and offered for re-use across the region following the live event
  • Enhanced digital training can help improve health outcomes for patients

 

Holzkirchen, March 20, 2017 – …

/by

Sandoz digital “Scientific Standalone” event will help drive access to medical information in field of cardiovascular therapies

  • Sandoz Scientific Standalone event — “Reach Targets, Save Lives” – aims at increasing access to information in the field of cardiovascular therapies in Central & Eastern Europe and Middle East & Africa (CEEMEA)
  • Lectures by leading cardiologists and internal medicine specialists will be recorded and offered for re-use across the region following the live event
  • Enhanced digital training can help improve health outcomes for patients

 

Holzkirchen, March 20, 2017 – …

/by

Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)

  • Three winners, chosen by expert panel at Wired Health 2017 in London, identified innovative approaches to address access challenges in Ghana, the Maldives and the Philippines.
  • Winning ideas proposed novel ways to use mobile technologies to connect patients with caregivers and essential medicines
  • Sandoz invited young people worldwide to “reimagine access to healthcare” – arguably the largest unmet medical need

London, March 13, 2017 – Sandoz, a Novartis Division, announced today the three winners of the inaugural Healthcare …

/by

New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine

  • Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*
  • Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis
  • Study reinforces strength of Sandoz pipeline and its key role in the broader Novartis immunology portfolio

Holzkirchen, 6 March 2017 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today …

/by